Targeting α-synuclein is an important therapeutic consideration in PD, highlighted by the fact that siRNA inhibition of the gene encoding this protein, Snca, in primary GFAP.HMOX1 astrocytes attenuated oxidative stress to levels observed in negative control and WT preparations [64]. This evidence concerns the gene GFAP and Parkinson disease.